Target intelligence / Profile preview

Solute carrier family 23 member 3–Non-homologous end joining factor 1 readthrough (SLC23A3-NHEJ1 readthrough)

Target
SLC23A3-NHEJ1 readthrough
Molecular classification
Other (not classified as receptor, transporter, enzyme, etc. as a distinct, functional fusion protein)
01

Overview

The "SLC23A3-NHEJ1 readthrough" (ENSG00000280537) refers to a predicted fusion transcript generated by transcriptional readthrough between the SLC23A3 and NHEJ1 genes. While both parent genes encode proteins with distinct cellular functions—SLC23A3 encodes a transmembrane transporter for hypoxanthine, and NHEJ1 encodes a DNA repair factor—there is no evidence that the readthrough transcript encodes a functional protein or that it has specific biological, disease, or pharmacological relevance. This entity is likely the result of annotation or prediction pipelines identifying rare transcriptional or splicing events, rather than a validated molecular target. No direct aliases, classifications, functions, associated diseases, drugs, biomarkers, or safety concerns exist for this readthrough product; any relevant information applies only to the separate parental genes[2][5][4].

Other names
SLC23A3-NHEJ1 readthroughSolute carrier family 23 member 3–non-homologous end joining factor 1 fusionENSG00000280537 (Ensembl gene ID)
02

Mechanism of action

None known.

03

Biological functions

Other (no specific, validated biological function for the readthrough)
04

Disease associations

Other (no validated disease associations for the readthrough)
05

Safety considerations

None described.As this is not a defined therapeutic target, there are no notable safety concerns or therapeutic challenges described.
06

Interacting drugs

None known for the readthrough product.

1 more in the full profile.

07

Biomarkers

None established for the readthrough protein.

Beyond the preview

Go deeper on Solute carrier family 23 member 3–Non-homologous end joining factor 1 readthrough (SLC23A3-NHEJ1 readthrough).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 23 member 3–Non-homologous end joining factor 1 readthrough (SLC23A3-NHEJ1 readthrough).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call